Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ' X1 O) w, t( V: X) ~) |( T( V- V
/ s$ N% L' m8 K+ Z/ J& W) H5 y
# x6 g$ E7 C1 ~( ^
Sub-category:
8 a) H) w& z8 f7 v4 B5 m. eMolecular Targets ) K1 q0 I9 R( `
. m5 S9 E* a: r8 L" a2 {
, o* b. h6 S# h" fCategory:
/ u' R: S% r7 J5 ]( oTumor Biology
; M/ P. q( ~$ ^2 u
# N/ }) u& l$ u0 M6 |* a/ q G) P- d* y+ g8 _! o
Meeting:' y- |$ ?: Q2 z% B7 k
2011 ASCO Annual Meeting
2 h, h' {5 u% U z6 X1 n
- a" e( z, r. c( q p
f2 L1 M3 g, M# k# g! e9 C8 `Session Type and Session Title:
% y, g$ ~ ?* E8 b# B+ R$ VPoster Discussion Session, Tumor Biology
2 U8 @* c! v* E# e. }
7 u7 x5 g1 a! }* y8 ?) E8 J' e( _- \
Abstract No:* {; N7 p) z% J" z# C7 b
10517
5 Q/ y# [& s) E w) d7 R3 P# w5 X q1 @8 @% i* m: {% E
; [4 W+ L7 E; A6 H: q
Citation:
/ B; k' v* r9 E% ]! N5 s; F" xJ Clin Oncol 29: 2011 (suppl; abstr 10517)
$ q3 E6 c+ d* d+ |
% s: x$ Z; v" L- i- m' `, d
! U/ ~, s" D' uAuthor(s):
% C. U- l( |4 p+ u7 V' MJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
; w& J5 Y9 v0 y8 i
1 P+ `3 g( S: e( |( K1 z& {, q/ l0 G' D' v% \' L$ n) |. s% U
6 m; q7 n, X% m
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
: O6 q8 l9 j5 `5 N: O& ]
# A2 R% w6 X3 l+ {4 f$ P5 pAbstract Disclosures
, }6 |3 X. m0 R; b0 e. \) h f- y- x
Abstract:, L& \0 [0 k. @, f9 r4 c
. r L+ F, Z# r, K. [
$ V- o4 Q0 `6 ]Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
8 U8 b h. i8 D. y0 v, R) d0 U7 Z0 L+ ]- d2 Y( D
, J( k& z6 K0 ]
|
5 n( I& c, N: Q5 h1 c0 ? W
显身卡
